Literature DB >> 10554320

Improved outcome following preoperative radiochemotherapy: 40.5 Gy accelerated hyperfractionation and 5-fluorouracil suppositories for patients with carcinoma of the lower rectum.

H Horie1, H Kashiwagi, F Konishi, K Furuta, A Ozawa, K Kanazawa.   

Abstract

The aim of this study was to determine the long-term effects of administering preoperative radiochemotherapy to patients with carcinoma of the lower rectum. The outcomes of 29 patients who underwent curative surgery for carcinoma of the lower rectum after receiving radiochemotherapy in the form of 40.5 Gy accelerated hyperfractionation and a total dose of 3 400 mg 5-fluorouracil given as suppositories, with or without hyperthermia, and 48 patients who underwent surgery alone, were retrospectively compared. The tumors in all the patients were histologically diagnosed as stage T3. The cumulative 5-year survival rate and 5-year local recurrence-free rate of the patients treated with radiochemotherapy plus surgery were significantly better than those of the patients treated by surgery alone, the respective values being 80.5% vs 59.8% (P = 0.0325) and 95.7% vs 61.4% (P = 0.0041). Dehiscence of the perineal wound, anastomotic leakage, and postoperative ileus occurred at similar frequencies in both groups; however, perineal wound healing after abdominoperineal resection was delayed in the patients treated with radiochemotherapy plus surgery at 42.7 days vs 25.4 days (P = 0. 0062). In conclusion, although the wound healing was delayed, preoperative radiochemotherapy is considered to be beneficial for patients with carcinoma of the lower rectum.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10554320     DOI: 10.1007/s005950050634

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  24 in total

1.  Possible role of potentiators in radiation therapy.

Authors:  M A BAGSHAW
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1961-05

2.  Improved survival with preoperative radiotherapy in resectable rectal cancer.

Authors:  B Cedermark; M Dahlberg; B Glimelius; L Påhlman; L E Rutqvist; N Wilking
Journal:  N Engl J Med       Date:  1997-04-03       Impact factor: 91.245

3.  Preoperative radiotherapy for adenocarcinoma of the rectosigmoid.

Authors:  K R Stevens; C V Allen; W S Fletcher
Journal:  Cancer       Date:  1976-06       Impact factor: 6.860

4.  Potential for hyperthermia and radiation therapy.

Authors:  H D Suit; L E Gerweck
Journal:  Cancer Res       Date:  1979-06       Impact factor: 12.701

5.  Complications of pelvic exenteration.

Authors:  J G Jakowatz; D Porudominsky; D U Riihimaki; M Kemeny; W A Kokal; P S Braly; J J Terz; J D Beatty
Journal:  Arch Surg       Date:  1985-11

6.  Omental transposition flap in colorectal carcinoma: adjunctive use in prevention and treatment of radiation complications.

Authors:  J E Russ; G L Smoron; J D Gagnon
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-01       Impact factor: 7.038

7.  The results of treatment of perineal recurrence of cancer of the rectum.

Authors:  H C Polk; J S Spratt
Journal:  Cancer       Date:  1979-03       Impact factor: 6.860

8.  Prevention of local recurrence by extended lymphadenectomy for rectal cancer.

Authors:  K Suzuki; T Muto; T Sawada
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

9.  A comparison of nonoperative vs. preoperative radiotherapy in rectal carcinoma. A 10-year randomized trial.

Authors:  J A Reis Neto; F A Quilici; J A Reis
Journal:  Dis Colon Rectum       Date:  1989-08       Impact factor: 4.585

10.  Local recurrence after potentially curative resection for rectal cancer in a series of 1008 patients.

Authors:  F T McDermott; E S Hughes; E Pihl; W R Johnson; A B Price
Journal:  Br J Surg       Date:  1985-01       Impact factor: 6.939

View more
  1 in total

1.  In situ delivery of thermosensitive gel-mediated 5-fluorouracil microemulsion for the treatment of colorectal cancer.

Authors:  Lu-Lu Wang; Shuai Huang; Hui-Hui Guo; Yan-Xing Han; Wen-Sheng Zheng; Jian-Dong Jiang
Journal:  Drug Des Devel Ther       Date:  2016-09-08       Impact factor: 4.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.